ArticleEuropean eating disorders review : the journal of the Eating Disorders Association2026
GDF15 Is Elevated in Eating Disorders and Is Involved in the Gut-Brain Axis via Ghrelin.
Article in European eating disorders review : the journal of the Eating Disorders Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pleiotropic effects of GDF-15 to regulate nutritional status: perspectives from body composition to nutrition-related disorders.British journal of biomedical science · 2026Review
- GDF15 Is Elevated in Eating Disorders and Is Involved in the Gut-Brain Axis via Ghrelin.European eating disorders review : the journal of the Eating Disorders Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveGDF15 induces anorexia and visceral discomfort, regulating appetite, food intake and potentially metabolic responses. However, its role in eating disorders remains unexplored.
methodA total of 145 participants were recruited (60 patients with anorexia nervosa, 20 with bulimia nervosa, 13 with binge eating disorder, 52 participants from the general population). Ghrelin and GDF15 serum levels were measured with immunosorbent assay kits.
resultsGhrelin was elevated in patients with an eating disorder compared to healthy controls (age and BMI-adjusted ANCOVA, F-value 4.084, p-value 0.008). GDF15 was significantly correlated with ghrelin (Spearman rho 0.430, p-value < 0.001) and BMI (rho = -0.176, p-value = 0.025). GDF15 predicted the BMI of patients with anorexia nervosa and individuals from the general population, again being elevated at lower BMI (linear regression beta -0.254, p-value 0.005). The effect of GDF15 on BMI was observed as under the mediation of ghrelin (direct effect -0.056, p-value 0.577; indirect effect -0.199, p-value < 0.001).
conclusionsPresent results provide novel insights into the role of GDF15 in eating disorders, describing its serum level in this clinical population for the first time. In addition, a positive correlation between GDF15 and ghrelin serum levels is also reported for the first time.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.